,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,675 Massachusetts Avenue,14th Floor,Cambridge,MA,02139,United States,857 242 1600,https://sperotherapeutics.com,Biotechnology,Healthcare,"Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",35,"{'maxAge': 1, 'name': 'Dr. Ankit  Mahadevia M.D., MBA', 'age': 41, 'title': 'Co-Founder & Chairman', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 1240383, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.29,1.29,1.265,1.31,1.29,1.29,1.265,1.31,0.0,0.889695,7.5294113,-2.6666667,411172,411172,354812,248380,248380,1.27,1.3,21500,800,67476864,0.81,3.18,1.2442031,1.4147,1.624525,0.0,0.0,USD,-4127750,-0.18594,36957488,52716300,1144209,1174635,1690761600,1693440000,0.0217,0.18938999,0.27238,2.24,0.026600001,1.042,1.2284068,1672444800,1703980800,1688083200,-10084000,0.17,-0.48,-0.07,-0.076,0.327,NMS,EQUITY,SPRO,SPRO,"Spero Therapeutics, Inc.","Spero Therapeutics, Inc.",1509629400,America/New_York,EDT,-14400000,1.28,8.0,5.0,6.67,7.0,2.2,buy,3,77690000,1.474,-12638000,6111000,4.605,5.1,54233000,11.155,1.143,-0.10188,-0.22235,-228125,12108000,0.363,0.24514,-0.23302999,-0.24422,USD,
1,675 Massachusetts Avenue,14th Floor,Cambridge,MA,02139,United States,857 242 1600,https://sperotherapeutics.com,Biotechnology,Healthcare,"Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",35,"{'maxAge': 1, 'name': 'Mr. Satyavrat  Shukla C.F.A.', 'age': 50, 'title': 'Pres, CEO & Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 823266, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.29,1.29,1.265,1.31,1.29,1.29,1.265,1.31,0.0,0.889695,7.5294113,-2.6666667,411172,411172,354812,248380,248380,1.27,1.3,21500,800,67476864,0.81,3.18,1.2442031,1.4147,1.624525,0.0,0.0,USD,-4127750,-0.18594,36957488,52716300,1144209,1174635,1690761600,1693440000,0.0217,0.18938999,0.27238,2.24,0.026600001,1.042,1.2284068,1672444800,1703980800,1688083200,-10084000,0.17,-0.48,-0.07,-0.076,0.327,NMS,EQUITY,SPRO,SPRO,"Spero Therapeutics, Inc.","Spero Therapeutics, Inc.",1509629400,America/New_York,EDT,-14400000,1.28,8.0,5.0,6.67,7.0,2.2,buy,3,77690000,1.474,-12638000,6111000,4.605,5.1,54233000,11.155,1.143,-0.10188,-0.22235,-228125,12108000,0.363,0.24514,-0.23302999,-0.24422,USD,
2,675 Massachusetts Avenue,14th Floor,Cambridge,MA,02139,United States,857 242 1600,https://sperotherapeutics.com,Biotechnology,Healthcare,"Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",35,"{'maxAge': 1, 'name': 'Ms. Tamara Lynn Joseph L.L.M.', 'age': 59, 'title': 'Chief Legal Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 775554, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.29,1.29,1.265,1.31,1.29,1.29,1.265,1.31,0.0,0.889695,7.5294113,-2.6666667,411172,411172,354812,248380,248380,1.27,1.3,21500,800,67476864,0.81,3.18,1.2442031,1.4147,1.624525,0.0,0.0,USD,-4127750,-0.18594,36957488,52716300,1144209,1174635,1690761600,1693440000,0.0217,0.18938999,0.27238,2.24,0.026600001,1.042,1.2284068,1672444800,1703980800,1688083200,-10084000,0.17,-0.48,-0.07,-0.076,0.327,NMS,EQUITY,SPRO,SPRO,"Spero Therapeutics, Inc.","Spero Therapeutics, Inc.",1509629400,America/New_York,EDT,-14400000,1.28,8.0,5.0,6.67,7.0,2.2,buy,3,77690000,1.474,-12638000,6111000,4.605,5.1,54233000,11.155,1.143,-0.10188,-0.22235,-228125,12108000,0.363,0.24514,-0.23302999,-0.24422,USD,
3,675 Massachusetts Avenue,14th Floor,Cambridge,MA,02139,United States,857 242 1600,https://sperotherapeutics.com,Biotechnology,Healthcare,"Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",35,"{'maxAge': 1, 'name': 'Mr. Stephen J. Dipalma M.B.A.', 'title': 'Interim CFO & Treasurer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.29,1.29,1.265,1.31,1.29,1.29,1.265,1.31,0.0,0.889695,7.5294113,-2.6666667,411172,411172,354812,248380,248380,1.27,1.3,21500,800,67476864,0.81,3.18,1.2442031,1.4147,1.624525,0.0,0.0,USD,-4127750,-0.18594,36957488,52716300,1144209,1174635,1690761600,1693440000,0.0217,0.18938999,0.27238,2.24,0.026600001,1.042,1.2284068,1672444800,1703980800,1688083200,-10084000,0.17,-0.48,-0.07,-0.076,0.327,NMS,EQUITY,SPRO,SPRO,"Spero Therapeutics, Inc.","Spero Therapeutics, Inc.",1509629400,America/New_York,EDT,-14400000,1.28,8.0,5.0,6.67,7.0,2.2,buy,3,77690000,1.474,-12638000,6111000,4.605,5.1,54233000,11.155,1.143,-0.10188,-0.22235,-228125,12108000,0.363,0.24514,-0.23302999,-0.24422,USD,
4,675 Massachusetts Avenue,14th Floor,Cambridge,MA,02139,United States,857 242 1600,https://sperotherapeutics.com,Biotechnology,Healthcare,"Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",35,"{'maxAge': 1, 'name': 'Mr. Timothy  Keutzer', 'age': 54, 'title': 'Chief Operating Officer', 'yearBorn': 1968, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.29,1.29,1.265,1.31,1.29,1.29,1.265,1.31,0.0,0.889695,7.5294113,-2.6666667,411172,411172,354812,248380,248380,1.27,1.3,21500,800,67476864,0.81,3.18,1.2442031,1.4147,1.624525,0.0,0.0,USD,-4127750,-0.18594,36957488,52716300,1144209,1174635,1690761600,1693440000,0.0217,0.18938999,0.27238,2.24,0.026600001,1.042,1.2284068,1672444800,1703980800,1688083200,-10084000,0.17,-0.48,-0.07,-0.076,0.327,NMS,EQUITY,SPRO,SPRO,"Spero Therapeutics, Inc.","Spero Therapeutics, Inc.",1509629400,America/New_York,EDT,-14400000,1.28,8.0,5.0,6.67,7.0,2.2,buy,3,77690000,1.474,-12638000,6111000,4.605,5.1,54233000,11.155,1.143,-0.10188,-0.22235,-228125,12108000,0.363,0.24514,-0.23302999,-0.24422,USD,
5,675 Massachusetts Avenue,14th Floor,Cambridge,MA,02139,United States,857 242 1600,https://sperotherapeutics.com,Biotechnology,Healthcare,"Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",35,"{'maxAge': 1, 'name': 'Ted  Jenkins', 'title': 'VP & Head of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.29,1.29,1.265,1.31,1.29,1.29,1.265,1.31,0.0,0.889695,7.5294113,-2.6666667,411172,411172,354812,248380,248380,1.27,1.3,21500,800,67476864,0.81,3.18,1.2442031,1.4147,1.624525,0.0,0.0,USD,-4127750,-0.18594,36957488,52716300,1144209,1174635,1690761600,1693440000,0.0217,0.18938999,0.27238,2.24,0.026600001,1.042,1.2284068,1672444800,1703980800,1688083200,-10084000,0.17,-0.48,-0.07,-0.076,0.327,NMS,EQUITY,SPRO,SPRO,"Spero Therapeutics, Inc.","Spero Therapeutics, Inc.",1509629400,America/New_York,EDT,-14400000,1.28,8.0,5.0,6.67,7.0,2.2,buy,3,77690000,1.474,-12638000,6111000,4.605,5.1,54233000,11.155,1.143,-0.10188,-0.22235,-228125,12108000,0.363,0.24514,-0.23302999,-0.24422,USD,
6,675 Massachusetts Avenue,14th Floor,Cambridge,MA,02139,United States,857 242 1600,https://sperotherapeutics.com,Biotechnology,Healthcare,"Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",35,"{'maxAge': 1, 'name': 'Mr. James P. Brady', 'title': 'Chief Human Resource Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.29,1.29,1.265,1.31,1.29,1.29,1.265,1.31,0.0,0.889695,7.5294113,-2.6666667,411172,411172,354812,248380,248380,1.27,1.3,21500,800,67476864,0.81,3.18,1.2442031,1.4147,1.624525,0.0,0.0,USD,-4127750,-0.18594,36957488,52716300,1144209,1174635,1690761600,1693440000,0.0217,0.18938999,0.27238,2.24,0.026600001,1.042,1.2284068,1672444800,1703980800,1688083200,-10084000,0.17,-0.48,-0.07,-0.076,0.327,NMS,EQUITY,SPRO,SPRO,"Spero Therapeutics, Inc.","Spero Therapeutics, Inc.",1509629400,America/New_York,EDT,-14400000,1.28,8.0,5.0,6.67,7.0,2.2,buy,3,77690000,1.474,-12638000,6111000,4.605,5.1,54233000,11.155,1.143,-0.10188,-0.22235,-228125,12108000,0.363,0.24514,-0.23302999,-0.24422,USD,
7,675 Massachusetts Avenue,14th Floor,Cambridge,MA,02139,United States,857 242 1600,https://sperotherapeutics.com,Biotechnology,Healthcare,"Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.",35,"{'maxAge': 1, 'name': 'Dr. Kamal  Hamed M.B.A., M.D., M.P.H.', 'age': 61, 'title': 'Chief Medical Officer', 'yearBorn': 1961, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.29,1.29,1.265,1.31,1.29,1.29,1.265,1.31,0.0,0.889695,7.5294113,-2.6666667,411172,411172,354812,248380,248380,1.27,1.3,21500,800,67476864,0.81,3.18,1.2442031,1.4147,1.624525,0.0,0.0,USD,-4127750,-0.18594,36957488,52716300,1144209,1174635,1690761600,1693440000,0.0217,0.18938999,0.27238,2.24,0.026600001,1.042,1.2284068,1672444800,1703980800,1688083200,-10084000,0.17,-0.48,-0.07,-0.076,0.327,NMS,EQUITY,SPRO,SPRO,"Spero Therapeutics, Inc.","Spero Therapeutics, Inc.",1509629400,America/New_York,EDT,-14400000,1.28,8.0,5.0,6.67,7.0,2.2,buy,3,77690000,1.474,-12638000,6111000,4.605,5.1,54233000,11.155,1.143,-0.10188,-0.22235,-228125,12108000,0.363,0.24514,-0.23302999,-0.24422,USD,
